Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.
What Ambea's new Danish care home means for the business
Ambea (OM:AMBEA) is expanding its Nordic footprint through Altiden, agreeing to operate a new 96 resident care home in Munkebo, Kerteminde Municipality, with opening planned for 2028.
This new facility comes on top of Altiden's roughly 50 existing elderly and social care operations in Denmark and sits within a business area that currently generates about SEK 1,300 million in annual revenue.
For you as an investor, the agreement highlights how Ambea is using improved market conditions in Denmark to add capacity in a measured way, tied to long term contracts in publicly funded care services.
See our latest analysis for Ambea.
Ambea's recent Danish expansion sits alongside a steady share price, with the stock at SEK137.0 after a 3.16% 1 month share price return and a 1 year total shareholder return of 34.46%. The 3 year total shareholder return of around 3x highlights how sentiment around the business has shifted over time.
If this kind of long term compounding interests you, it could be worth broadening your search and checking out the 95 top founder-led companies
With Ambea trading at SEK137, sitting below an average analyst price target of SEK158.33 and carrying a high intrinsic value discount score, the question is simple: is this a genuine opportunity or is future growth already reflected?
Most Popular Narrative: 13.5% Undervalued
Ambea's most followed valuation narrative pins fair value at SEK158.33 per share, compared with the last close at SEK137, and links that gap directly to long term demand in Nordic care services and a growing project pipeline.
The company's strong and expanding pipeline of new care homes and units, combined with legislative initiatives like Denmark's new Elderly Care Act and ongoing contract wins, positions Ambea for significant organic growth in its core markets, which is likely to lift top line growth and utilization rates over the next 12 to 24 months.
Curious what earnings path, margin lift, and future P/E multiple need to line up for that SEK158.33 fair value to hold up over time? The narrative pulls together projected revenue growth, a step up in profitability, and a future valuation multiple that sits below a broad healthcare benchmark, all filtered through a 5.8% discount rate.
Result: Fair Value of SEK158.33 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear risks if acquisition driven growth raises debt and integration costs, or if public sector budgets tighten and place pressure on contract terms.
Find out about the key risks to this Ambea narrative.
Next Steps
The story so far mixes optimism with caution, so consider reviewing the full picture for yourself using the 4 key rewards and 2 important warning signs instead of remaining on the sidelines.
Looking for more investment ideas?
If Ambea is on your radar, do not stop there. Use the Simply Wall Street Screener to uncover more focused ideas that fit your style and risk comfort.
-
Target dependable cash generators by scanning for companies with strong income potential and resilient payouts using the 480 dividend fortresses
-
Zero in on quality at a sensible price by filtering for financially robust companies that currently look mispriced with the 231 high quality undervalued stocks
-
Prioritize sleep at night holdings by focusing on businesses with steadier risk profiles through the 298 resilient stocks with low risk scores
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AMBEA.ST .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
